Products and Services for Cell and Gene Therapy –
From Discovery to Commercialization

Therapeutic, serum-free cell-culture media enabling robust, consistent and cost-efficient processes for cell and gene therapies.

Research grade hematopoietic, immune and stem cells with related media, from immediately available cryopreserved cells to made-to-order fresh whole tissue.

An electroporation-based transfection platform for the non-viral, ex-vivo genetic modification of human primary cells. Ranging from small to large scale formats, allowing you to easily translate research results into therapeutic applications.

An extensive service offering that includes tailored process and analytical development, cGMP manufacturing, and regulatory services.

The Bacterial Endotoxin Test (BET) is a crucial safety requirement for end-product release. Our regulatory compliant BET products and services ensure your cell therapies can be used with confidence.

A configurable and flexible electronic batch record solution for paperless data capture in laboratories and manufacturing facilities with GMP compliance and tracking at its core.

A functionally closed and automated platform for cell therapy manufacturing, providing flexibility and scalability to your process and allowing you to substantially reduce costs.

Learn how Lonza’s Cocoon^® Platform, 4D-Nucleofector^TM LV Unit and X-VIVO^TM 15 Medium are integrated to enable non-viral genetic modification and subsequent expansion of primary T cells in a functionally-closed, automated workflow.

Learn from our peer-reviewed article, published by Cell & Gene Therapy Insights, how serum-free media can support large-scale, regulatory compliant expansion processes. Download the PDF below or read the article on the publisher's website.

Learn about Lonza's approach digitalizing our cell therapy manufacturing operations and the future plans for the MODA-ES^TM System within Lonza.

Join leading cell therapy thought leaders as they share their insights and lessons learned on advancing therapies from bench to bedside, the challenges they face, and where in their view the fast-evolving cell therapy field is heading.

Presented by CAR-TCR Digital Week

Learn from Senior Scientist Jerome Jacques how Lonza's new TheraPEAK^TM SfAAV^TM Medium can help to streamline and accelerate the production of AAV in Sf9 cells.

Cell and gene therapy are a hot topic, but are you aware of the requirements around endotoxin testing for these products? Here is a short overview.